Mexidol ampoules 5% 2ml №50

Antioxidant drug

Antioxidant

Mechanism of action

Antioxidant drug. It has antihypoxic, membrane-protective, nootropic, anticonvulsant and anxiolytic effects, increases the body's resistance to stress. The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, impaired cerebral circulation, intoxication with alcohol and antipsychotics / neuroleptics /).

Mexidol^® improves brain metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL.

Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of the drug Mexidol^® due to its antihypoxic, antioxidant and membrane-protective action.The drug inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of "lipid-protein", reduces the viscosity of the membrane, increases its fluidity. Mexidol^® modulates the activity of membrane enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, promotes preservation of structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Mexidol^® increases dopamine content in the brain. It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with an increase in the content of ATP, creatine phosphate and activation of energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

Mexidol^® normalizes metabolic processes in ischemic myocardium, reduces the area of ​​necrosis, restores and improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic area, reduces the effects of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitropreparatov. Mexidol^® contributes to the preservation of retinal ganglion cells and optic nerve fibers with progressive neuropathy, the causes of which are chronic ischemia and hypoxia.It improves the functional activity of the retina and optic nerve, increasing visual acuity.

Suction

With the introduction of Mexidol in doses of 400-500 mg C_max in plasma it is 3.5–4.0 mcg / ml and is reached within 0.45–0.5 h.

Distribution

After i / m injection, the drug is determined in the blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 h.

Removal

Excreted from the body with urine mainly in the glucuron conjugated form and in small quantities in unchanged form.

Indications and usage

- acute disorders of cerebral circulation;

- traumatic brain injury, the consequences of traumatic brain injury;

- encephalopathy;

- vegetative dystonia syndrome;

- slight cognitive disorders of atherosclerotic genesis;

- anxiety disorders in neurotic and neurosis-like states;

- acute myocardial infarction (from the first day) as part of complex therapy;

- primary open-angle glaucoma of various stages, as a part of complex therapy;

- relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotics;

- acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) as part of complex therapy.

Mexidol^® enter in / m or / in (struino or drip).To prepare the solution for infusion, the drug should be diluted in a 0.9% solution of sodium chloride.

Struino Mexidol^® administered slowly over 5-7 minutes, drip - at a speed of 40-60 drops / min. The maximum daily dose should not exceed 1200 mg.

At acute disorders of cerebral circulation Mexidol^® used in the first 10-14 days in / in the drip 200-500 mg 2-4 times / day, then in the / m 200-250 mg 2-3 times / day for 2 weeks.

At traumatic brain injury and the effects of traumatic brain injury Mexidol^® used within 10-15 days in / in the drip at 200-500 mg 2-4 times / day.

At dyscirculatory encephalopathy in decompensation phase Mexidol^® apply in / in the jet or drip in a dose of 200-500 mg 1-2 times / day for 14 days, then - in the / m 100-250 mg / day for the next 2 weeks.

For course prophylaxis of dyscirculatory encephalopathy Mexidol^® administered in / m in a dose of 200-250 mg 2 times / day for 10-14 days.

At mild cognitive impairment at elderly patients and at anxiety disorders Mexidol^® administered in the / m dose of 100-300 mg / day for 14-30 days.

At acute myocardial infarction as part of complex therapy Mexidol^® administered in / in or intramuscularly for 14 days, against the background of traditional therapy of myocardial infarction, including nitrates, beta-adrenoblockers, ACE inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.

In the first 5 days, to achieve the maximum effect, it is desirable to introduce the drug in / in the next 9 days Mexidol^® may be injected in / m.

In / in the introduction of the drug produced by drip infusion, slowly (to avoid side effects) on a 0.9% solution of sodium chloride or 5% dextrose (glucose) in a volume of 100-150 ml for 30-90 minutes If necessary, a slow jet injection of the drug for at least 5 minutes is possible.

Drug administration (intravenously or intramuscularly) is carried out 3 times / day every 8 hours. The daily therapeutic dose is 6–9 mg / kg body weight / day, a single dose — 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single - 250 mg.

At open-angle glaucoma of various stages in the complex therapy Mexidol^® enter in / m at 100-300 mg / day 1-3 times / day for 14 days.

At alcohol withdrawal syndrome Mexidol^® Injected in a dose of 200-500 mg / drip or intramuscularly 2-3 times / day for 5-7 days.

At acute antipsychotic intoxication Mexidol^® Injected into / in the dose of 200-500 mg / day for 7-14 days.

At acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) Mexidol^® appoint in the first days both in the preoperative, and in the postoperative period. The doses administered depend on the form and severity of the disease, the extent of the process, the clinical course variants. Removal of the drug should be made gradually, only after a steady positive clinical and laboratory effect.

At acute edematous (interstitial) pancreatitis Mexidol^® appoint 200-500 mg 3 times / day in / in drip (in isotonic sodium chloride solution) and in / m.

At mild necrotizing pancreatitis Mexidol^® appoint 100-200 mg 3 times / day in / in drip (in isotonic sodium chloride solution) and in / m.

At moderate necrotizing pancreatitis - 200 mg 3 times / day in / in drip (in isotonic sodium chloride solution).

At necrotizing pancreatitis heavy current - in the pulse dosage of 800 mg on the first day, with a double administration regimen, further - 200-500 mg 2 times / day with a gradual decrease in the daily dose.

At extremely severe form of necrotic pancreatitis initial dose of 800 mg / day until persistent relief of manifestations of pancreatic shock, to stabilize the state - 300-500 mg 2 times a day in / in the drip (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

From the digestive system: nausea and dryness of the oral mucosa may occur.

Other: allergic reactions, drowsiness.

- acute abnormal liver function;

- acute renal dysfunction;

- increased individual sensitivity to the drug.

Strictly controlled clinical studies of the safety of the drug Mexidol^® in children, during pregnancy and lactation was not carried out.

Mexidol^® not recommended for use during pregnancy and lactation (breastfeeding) due to insufficient knowledge of the drug.

The drug is contraindicated in acute liver dysfunction.

The drug is contraindicated in acute renal dysfunction.

In some cases, especially in predisposed patients with bronchial asthma, with increased sensitivity to sulfites, severe hypersensitivity reactions may develop.

Overdose may cause drowsiness.

Mexidol^® enhances the action of anxiolytics benzodiazepine derivatives, anti-Parkinsonian (levodopa) and anticonvulsant (carbamazepine) agents.

Mexidol^® reduces the toxic effects of ethyl alcohol.

The drug should be stored out of the reach of children, dry, protected from light, at a temperature not exceeding 25 ° C. Shelf life - 3 years. Do not use after the expiration date printed on the package.

The drug is available on prescription.